With both Tandem and Insulet reporting earnings yesterday two messages are beginning to emerge when it comes to the insulin pump market. First, both Tandem and Insulet are gaining momentum each doing well with their existing products while developing exciting new products. Next if the folks in Northridge aren’t worried, they should be. Medtronic may be king of the hill for the moment but uneasy is the king who wears the crown.
Both Tandem and Insulet are inching ever closer to having their own hybrid closed loop systems, systems that work with the Dexcom sensor. We were . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.